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meters (e.g., test sensitivities/speciﬁcities) were collected from lit-
erature and expert opinion. Medical service costs were estimated
using published Medicare statistics, or paid amounts from a large
claims database covering approximately two million lives in 
the US. Cost analyses were conducted both from Medicare’s per-
spective and private third party payers’ perspective. Breakeven
prices of BMIPP were calculated. All costs were adjusted to 2003
USD using CPI. RESULTS: Compared to pre-admission standard
of care, SPECT with BMIPP has lower false positive and false
negative rates. Equivocal ACI patients tested by SPECT with
BMIPP spend 19 hours less per visit in ED/CPU. The breakeven
price of BMIPP is $927 per test from private third party payers’
perspective; and $554 from Medicare’s perspective. The likeli-
hood of malpractice litigation associated with ACI misdiagnosis
is 60% less for SPECT with BMIPP. CONCLUSIONS: Adoption
of SPECT with BMIPP for the diagnosis of ACI in ED/CPU may
reduce health care costs to third party payers and employers,
decrease patient time spent in ED/CPU, improve the efﬁciency 
of ED/CPU, and reduce malpractice litigation risk. It may also
signiﬁcantly reduce costs and risks associated with chest pain
patients admitted to the hospital following equivocal diagnosis
in the ED/CPU setting.
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OBJECTIVES: Acute coronary syndromes (ACS) are a major
cause of morbidity and mortality in Western Europe, imposing
signiﬁcant costs on health care providers. This study aims to esti-
mate costs (including medications prescribed, intervention rates
and hospital utilization) and health outcomes of ACS during 
the ﬁrst year following diagnosis. Perspective of the health 
care provider is used throughout. Countries examined were the
United Kingdom (UK), France, Germany, Italy and Spain.
METHODS: Treatment pathways for ACS patients, including
investigations, revascularisation and medical management, 
were developed. Resource use was multiplied by the unit cost of
the resource for all interventions and, since these factors vary
between countries, country-speciﬁc inputs (where possible) from
2002 data were used. RESULTS: Estimated number of deaths in
the ﬁrst year following ACS diagnosis ranged from around
22,500 in Spain to over 90,000 in Germany. Although the
number of patients undergoing percutaneous coronary interven-
tion (PCI) is lower in the UK (9%) than the rest of Western
Europe (Germany was highest at 62%), differences are narrow-
ing, as the UK’s PCI rate is increasing more rapidly than that 
of other countries. Largest contributors to total costs are 
hospital stay (particularly intensive and coronary care units) 
and revascularisation procedures. Pharmaceuticals were esti-
mated at 14–25% of ACS total cost. Models were most 
sensitive to changes in ACS incidence, death rate before hospi-
talization, and hospital unit costs. Total cost of ACS in the UK
is estimated around 1.8€ billion, compared with 1.3€ billion in
France, 3.2€ billion in Germany, 2.9€ billion in Italy and 1.0€
billion in Spain. CONCLUSION: Morbidity and mortality, and
cost of ACS are substantial. ACS contributes a large proportion
towards total health care expenditure of Western European
economies. Differences in expenditure between countries can 
be accounted for by disparities in population, incidence and
resource use.
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OBJECTIVE: Consensus treatment guidelines recommend most
patients with acute coronary syndrome (ACS) receive antiplatelet
therapy, statins, and beta-blockers for prevention of secondary
events. The goal of this review was to examine prescribing pat-
terns of these agents from published naturalistic studies and
compare to guideline recommendations. METHODS: An OVID
Medline search was conducted from 1995 to 2004 to identify
published naturalistic studies of ACS treatment that contained
detailed drug utilization data. Drug utilization patterns were
examined for two aspects: associated therapeutic strategy
(medical therapy or percutaneous coronary intervention [PCI])
and initiation of drug therapy (acutely or as chronic therapy after
hospital discharge). RESULTS: Four sources that contained 
sufﬁcient details on drug utilization were identiﬁed. Data were
from US and worldwide studies. Beta-blockers had the highest
overall utilization (50–87% acute; 41–77% chronic). Statins
were administered to 43–57% of patients acutely and 44–68%
chronically. Insufﬁcient data were available to examine associ-
ated therapeutic strategy for beta-blockers and statins. Clopido-
grel use, with or without aspirin, ranged from 16–30% acutely.
In the subgroup of patients who received PCI, clopidogrel use in
the hospitalization period ranged from 51–83%. The percentage
of ACS patients who received clopidogrel chronically was
38–66%, however in the subgroup of patients who underwent
PCI, up to 83% received clopidogrel after hospital discharge.
Insufﬁcient data were available to examine duration of therapy.
CONCLUSIONS: Recent treatment guidelines recommend use
of beta-blockers, statins, and antiplatelet therapy in ACS
patients. Some of the data reviewed here predates the most recent
guidelines but they suggest a gap between the usual care setting
and treatment guidelines. The largest discrepancy appears to be
with chronic statin use and clopidogrel use in ACS patients who
do not undergo PCI. Few data regarding duration of therapy are
available. Continued guideline education and reinforcement
along with quality improvement measures are needed.
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OBJECTIVES: Long-term antiplatelet therapy is typically con-
sidered standard of care for secondary prevention of cardiac
events in acute coronary syndrome (ACS) patients. The Euro-
pean Society of Cardiology consensus treatment guidelines in
2002 support the use of clopidogrel in many of these patients.
The goal of this descriptive study was to examine clopidogrel
patterns of use in ACS patients in the UK. METHODS: The data
source was the IMS Health, Disease Analyzer Mediplus—UK
database. This database contains nearly two-million de-identi-
ﬁed patient records and 58 million prescriptions continuously
collected from approximately 560 participating general prac-
tices. The study time period was January 01, 1999 to November
30, 2003. The index ACS event was identiﬁed using ICD-10
codes for unstable angina and acute myocardial infarction.
Patients were included if they had at least six-months of data
both before and after the index ACS event, and at least one pre-
scription for clopidogrel after the event. RESULTS: A total of
9591 patients were included in the ACS cohort and 1110 had at
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least one clopidogrel prescription (11.6%) and met inclusion cri-
teria. Mean age was 67.1 years; 65.8% were male. Commonly
recorded comorbidities included: diabetes, angina, coronary
heart disease, and hypertension. Mean length of clopidogrel
therapy was 144 days. Patterns of use analysis found 42.5% of
patients stopped therapy (deﬁned as not on clopidogrel 28 days
prior to end of follow up). A gap in therapy was seen in 82.9%
(deﬁned as late reﬁlls >14 days apart). Concomitant cardiovas-
cular drug therapies included: ACE inhibitor (34.1%), beta-
blocker (12.9%), and statin (51%). CONCLUSIONS: This
descriptive study suggests clopidogrel is substantially underuti-
lized in ACS patients. Furthermore, patients had poor long-term
adherence to therapy as demonstrated by the number who
stopped therapy or had gaps. A large gap exists between current
practice and suggested treatment guidelines.
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OBJECTIVES: This research uses a Markov model of acute 
coronary syndrome (ACS) to determine the magnitudes of cost
drivers affected by new treatments. METHODS: A Markov
model was built using TreeAge Pro Healthcare and parameter-
ized to replicate the Clopidogrel in Unstable angina to prevent
Recurrent ischemic Events (CURE) trial. The model reports
results at 30 days, then every six-months over three-years for
clopidogrel plus aspirin vs. a hypothetical alternative. Reduc-
tions in risk for ﬁve events are analyzed: myocardial infarction
(MI), initial and subsequent percutaneous coronary intervention
(PCI), refractory ischemia, and stroke. Modeled risks and costs
of coronary bypass surgery and bleeding complication are not
modiﬁed. Resulting states include: no event, post each event type,
various cardiac deaths, and non-cardiac death. RESULTS: The
effects on costs of reducing relative risks of each event (and all
ﬁve together) by 10% and 20% are evaluated. Cost offsets at
one and three-years are highest for initial PCI ($239, $724;
2.0%, 2.8% of total costs for time period) for a 20% six-month
risk reduction. All other one-year offsets are less than 1.0%. Ten
percent reductions produce nearly half the cost savings. Total
savings for a 20% reduction in all ﬁve events are ($493, $1530;
4.1%, 5.8%) at one and three-years. If, instead of reducing risks
after the initial 30-day period, a 20% reduction in 30-day risk
of PTCA is modeled, then costs decrease by $389, $480, and
$616 at 30 days, one and three-years, respectively. CONCLU-
SIONS: In this model, initial PCI inﬂuences cost more than MI,
refractory ischemia, subsequent PCI, or stroke, but all are clini-
cally important. Knowing the relationship between event costs
and risk reductions can help estimate the potential cost impact
of new treatments.
CARDIOVASCULAR DISEASE—Angioplasty
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OBJECTIVES: The Clopidogrel for the Reduction of Events
During Observation (CREDO) trial showed that clopidogrel
loading prior to percutaneous coronary intervention (PCI) with
one-year treatment after PCI reduced the combined risk of death,
myocardial infarction (MI) or stroke. The purpose of this study
was to evaluate the economic impact of clopidogrel based on
CREDO in Switzerland, Belgium, Italy, and France. METHODS:
We used clinical outcomes and resource use from CREDO com-
bined with external survival data to assess the long-term cost-
effectiveness of clopidogrel. A total of 2116 patients with
coronary artery disease were randomized to clopidogrel loading
before PCI plus one year therapy (n = 1053) vs. 28 days clopi-
dogrel followed by placebo (n = 1063). All patients received
clopidogrel day zero to 28. In all, 89 (8.45%) patients in 
the treatment arm and 122 (11.48%) in the placebo group 
had an event (RRR 26.9%, 95% CI 3.9%–44.4%). Hospital-
izations were assigned a Diagnostic Related Group (DRG)
through a DRG grouper. Unit costs were developed in each
country and applied to all patients of the CREDO study. Lost
life expectancy associated with death, MI and stoke was 
estimated from Saskatchewan data and discounted 3%. Cost
effectiveness was expressed as the cost per event avoided and as
cost per Life year saved (LYS). RESULTS: The cost effectiveness
of one year use of clopidogrel in addition to a clopidogrel load-
ing strategy prior to PCI vs. placebo ranges from 15,765€ to
26,074€/event prevented. The cost per LYS is 2483€/LYS in
Belgium, 2502€/LYS in France; 2552€/LYS in Italy; 2659€/LYS
in Switzerland based on Saskatchewan projection. CONCLU-
SION: Clopidogrel used prior to PCI and for one year thereafter
is a cost effective strategy. Consistent results are found in the
four countries studied.
CARDIOVASCULAR DISEASE—Arrhythmia
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OBJECTIVE: The objective of the study was to analyze annual
health resource utilization and costs of patients with atrial ﬂutter.
While the majority of atrial ﬂutter research has focused on
various pharmacologic, cardioversion, and catheter ablation
treatment options, the costs associated with treating atrial ﬂutter
patients have not been previously reported. METHODS: All
patients receiving a diagnosis of atrial ﬂutter (ICD-9 427.32)
between January 1, and December 31, 2002 were identiﬁed from
a nationally representative private payer database (IHCIS,
Waltham, MA). Patients <18 years of age or not continuously
enrolled in a health plan for one year following the atrial ﬂutter
diagnosis were removed from the analysis. Total one-year health
resource use and costs, including hospital inpatient, outpatient,
professional, ancillary, and pharmacy services, were measured
from a third-party payer perspective. RESULTS: The study
included 4945 patients with an atrial ﬂutter diagnosis. The
average age was 62 years; 65% were male. The top co-morbid
conditions were atrial ﬁbrillation (72.3%), hypertension (55%),
and neoplasms (27%). Average total one-year medical costs for
atrial ﬂutter patients were $25,652 +/-$44,814, of which inpa-
tient hospitalizations comprised almost 50% of the total cost.
Over half of patients were hospitalized with mean length of stay
of 6.78 +/-20.73 days, 83% had at least one outpatient visit,
while almost all patients had a physician visit and 71% required
at least one pharmacy visit during the one-year follow-up. 
